$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000139047816000134 Filed on August 09, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$0.00	$3.382M
YoY Change	-100.0%	45.09%
Cost Of Revenue		$468.0K
YoY Change		34.87%
Gross Profit		$2.914M
YoY Change		46.88%
Gross Profit Margin		86.16%
Selling, General & Admin	$3.117M	$1.886M
YoY Change	65.27%	-80.35%
% of Gross Profit		64.72%
Research & Development	$6.175M	$7.197M
YoY Change	-14.2%	-10.81%
% of Gross Profit		246.98%
Depreciation & Amortization	$0.00	$560.0K
YoY Change	-100.0%	143.48%
% of Gross Profit		19.22%
Operating Expenses	$9.292M	$9.083M
YoY Change	2.3%	-48.59%
Operating Profit	-$9.292M	-$9.083M
YoY Change	2.3%	-42.45%
Interest Expense	$13.87M	-$4.490M
YoY Change	-408.91%	22.34%
% of Operating Profit
Other Income/Expense, Net	$5.500M	$83.00K
YoY Change	6526.51%	-100.42%
Pretax Income	$8.280M	-$13.49M
YoY Change	-161.38%	-15.42%
Income Tax
% Of Pretax Income
Net Earnings	$5.389M	-$15.66M
YoY Change	-134.41%	-21.47%
Net Earnings / Revenue		-463.04%
Basic Earnings Per Share	$0.59	-$0.10
Diluted Earnings Per Share	$0.58	-$1.566B
COMMON SHARES
Basic Shares Outstanding	9.102M shares	161.4M shares
Diluted Shares Outstanding	9.274M shares	161.4M shares

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.60M	$45.30M
YoY Change	-56.73%	15.56%
Cash & Equivalents	$19.59M	$45.28M
Short-Term Investments
Other Short-Term Assets	$25.70M	$2.600M
YoY Change	888.46%	36.84%
Inventory		$1.426M
Prepaid Expenses
Receivables		$1.818M
Other Receivables		$0.00
Total Short-Term Assets	$45.28M	$51.12M
YoY Change	-11.42%	17.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$259.0K	$532.0K
YoY Change	-51.32%	-14.61%
Goodwill	$5.898M	$6.069M
YoY Change	-2.82%	2.9%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$8.200M
YoY Change	-97.56%	8100.0%
Total Long-Term Assets	$28.49M	$50.85M
YoY Change	-43.96%	38.95%
TOTAL ASSETS
Total Short-Term Assets	$45.28M	$51.12M
Total Long-Term Assets	$28.49M	$50.85M
Total Assets	$73.78M	$102.0M
YoY Change	-27.65%	27.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.273M	$2.318M
YoY Change	-45.08%	13.85%
Accrued Expenses	$4.703M	$12.92M
YoY Change	-63.61%	9.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$23.16M	$4.079M
YoY Change	467.71%	0.07%
Total Short-Term Liabilities	$47.22M	$38.11M
YoY Change	23.9%	14.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.546M
YoY Change	-100.0%	-57.59%
Other Long-Term Liabilities	$800.0K	$6.900M
YoY Change	-88.41%	-8.0%
Total Long-Term Liabilities	$800.0K	$2.546M
YoY Change	-68.58%	-57.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$47.22M	$38.11M
Total Long-Term Liabilities	$800.0K	$2.546M
Total Liabilities	$53.46M	$52.60M
YoY Change	1.63%	1.23%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$314.7M	$294.9M
YoY Change	6.7%	26.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M
YoY Change	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares
Shareholders Equity	$20.32M	$49.37M
YoY Change
Total Liabilities & Shareholders Equity	$73.78M	$102.0M
YoY Change	-27.65%	27.02%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	$5.389M	-$15.66M
YoY Change	-134.41%	-21.47%
Depreciation, Depletion And Amortization	$0.00	$560.0K
YoY Change	-100.0%	143.48%
Cash From Operating Activities	-$11.49M	-$11.86M
YoY Change	-3.12%	-8.56%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$450.0K
YoY Change	-100.0%	-245.16%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$500.0K
YoY Change	-100.0%
Cash From Investing Activities	$0.00	-$50.00K
YoY Change	-100.0%	-83.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.630M	4.330M
YoY Change	-183.83%	21550.0%
NET CHANGE
Cash From Operating Activities	-11.49M	-11.86M
Cash From Investing Activities	0.000	-50.00K
Cash From Financing Activities	-3.630M	4.330M
Net Change In Cash	-15.12M	-7.580M
YoY Change	99.47%	-42.84%
FREE CASH FLOW
Cash From Operating Activities	-$11.49M	-$11.86M
Capital Expenditures	$0.00	$450.0K
Free Cash Flow	-$11.49M	-$12.31M
YoY Change	-6.66%	-2.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	213968953	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
	dei	Trading Symbol TradingSymbol	GALE
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-3115000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	10520000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-238000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	5327000	USD
CY2016Q2	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	461000	shares
CY2015Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6142000	USD
CY2016Q2	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	815000	USD
CY2015Q4	gale	Contract Research Payable ContractResearchPayable	3294000	USD
CY2016Q2	gale	Contract Research Payable ContractResearchPayable	3208000	USD
CY2013Q2	gale	Debt Instrument Cash Facility Fee DebtInstrumentCashFacilityFee	0.01
CY2015Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	83000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-238000	USD
CY2016Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	5497000	USD
CY2013Q2	gale	Debt Instrument Cash Final Payment DebtInstrumentCashFinalPayment	0.055
CY2013Q2	gale	Debt Instrument Term Interest Only DebtInstrumentTermInterestOnly	P12M
CY2015Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-279383000	USD
CY2016Q2	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-290487000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	3755000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y9M15D
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	5327000	USD
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-10520000	USD
	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	502000	shares
CY2013Q2	gale	Classof Warrantor Right Average Market Price Used For Exercise Price ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice	P20D
	gale	Classof Warrantor Right Expired ClassofWarrantorRightExpired	31000	shares
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	15643000	shares
CY2013Q2	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P7Y
CY2016Q3	gale	Common Stock Additional Shares Authorized CommonStockAdditionalSharesAuthorized	75000000	shares
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	324000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	0	USD
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	324000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	10296000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	5590000	USD
CY2015Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	14518000	USD
CY2016Q2	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	9264000	USD
CY2015Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	14518000	USD
CY2016Q2	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	9264000	USD
	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	5590000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	0.87
CY2015Q4	gale	Gale401rights GALE401rights	9255000	USD
CY2016Q2	gale	Gale401rights GALE401rights	9255000	USD
CY2015Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2016Q2	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
	gale	Increase Decreasein Restricted Cashfor Financing Activities IncreaseDecreaseinRestrictedCashforFinancingActivities	0	USD
	gale	Increase Decreasein Restricted Cashfor Financing Activities IncreaseDecreaseinRestrictedCashforFinancingActivities	24000000	USD
CY2015Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	4267000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	3115000	USD
CY2016Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	-14392000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-10520000	USD
CY2015Q2	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	0	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	233000	USD
CY2015Q1	gale	Numberof Shares Per Unit NumberofSharesPerUnit	0.50	shares
CY2016Q2	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	10923000	shares
	gale	Paymentson Disposalof Productive Assets PaymentsonDisposalofProductiveAssets	1050000	USD
CY2015Q2	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	5400000	USD
CY2015Q2	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	40800000	USD
CY2016Q1	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	20200000	USD
CY2014Q4	gale	Purchase Agreement Term PurchaseAgreementTerm	P36M
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	0	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue		USD
CY2015Q1	gale	Stock Issued During Period Shares Overallotment Option StockIssuedDuringPeriodSharesOverallotmentOption	1826923	shares
CY2015Q2	gale	Stock Issued During Period Shares Overallotment Option StockIssuedDuringPeriodSharesOverallotmentOption	3653846	shares
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	1000000	shares
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1597000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1273000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5292000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4703000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	435000	USD
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	560000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	296730000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	314639000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1278000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5590000	USD
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33719000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33719000	shares
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27959000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47727000	shares
CY2015Q4	us-gaap	Assets Assets	82144000	USD
CY2016Q2	us-gaap	Assets Assets	73778000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	53621000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	45284000	USD
CY2015Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	392000	USD
CY2016Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	83000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23650000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45279000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29730000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19590000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19600000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	21629000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10140000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-534000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-1050000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3980000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-7119000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.47
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.08
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.42
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.51
CY2016Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.60	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1826923	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22308000	shares
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	37418000	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	59111000	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3653846	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	162581753	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	182512117	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161906753	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	181837117	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	9083000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	17995000	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	9292000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	18260000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0845
CY2013Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30M
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5418000	USD
CY2016Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5418000	USD
CY2015Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	171000	USD
CY2016Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	218000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	181000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	777000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1535000	USD
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	935000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7713
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0126
CY2015Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2016Q2	us-gaap	Goodwill Goodwill	5898000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-13474000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-21780000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	8278000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4824000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.15
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.05
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.03
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2186000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-4417000	USD
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2889000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-6280000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.03
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.03
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-825000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-324000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1380000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-589000	USD
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-437000	USD
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	839000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	0	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-19900000	USD
	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	USD
	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-21700000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-256000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-141000	USD
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2765458	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	677279	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	21700000	USD
CY2016Q2	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	USD
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-207000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-432000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-519000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-611000	USD
	us-gaap	Interest Paid InterestPaid	312000	USD
	us-gaap	Interest Paid InterestPaid	606000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	28000	USD
CY2016Q2	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2015Q4	us-gaap	Liabilities Liabilities	68631000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	53457000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82144000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73778000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57071000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	47224000	USD
CY2015Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	5925000	USD
CY2016Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3727000	USD
CY2015Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	25000000	USD
CY2016Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5100000	USD
	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	26800000	USD
CY2015Q2	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	0	USD
	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	0	USD
CY2016Q2	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1800000	USD
	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1800000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4739000	USD
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	23157000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45613000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15623000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-568000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1056000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-34000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23416000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24707000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19436000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17588000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-15660000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26197000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	5389000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11104000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9083000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17995000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9292000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18260000	USD
CY2015Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-4391000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-3785000	USD
CY2016Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	17570000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	13436000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	534000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1398000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1210000	USD
	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	21700000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	49000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47416000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20189000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	23641000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	38000000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	110000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	78000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	261000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	335000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	259000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1914000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4779000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7197000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13022000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6175000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11618000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	401000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	24400000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	24401000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	24000000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1886000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4973000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3117000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6642000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7563
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.742
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.763
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7332
	us-gaap	Share Based Compensation ShareBasedCompensation	759000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1278000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M4D
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0169
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5970000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.97
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	56000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2952000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	166000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.86
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13262000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10309000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.58
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.44
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.57
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.07
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.27
CY2015Q1	us-gaap	Share Price SharePrice	1.56
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2016Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.10
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	24358974	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	19772727	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	167000	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	557000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	78000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21800000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	20189000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	261000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	13513000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	20321000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13513000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20321000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2016Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2016Q2	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3442737	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	161383398	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148647581	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	185477330	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	180703456	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	161383398	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148647581	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	182034593	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	180703456	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> — Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June 30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company’s cash equivalents were invested in money market mutual funds. The Company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June 30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001390478-16-000134-index-headers.html	Edgar Link	pending
0001390478-16-000134-index.html	Edgar Link	pending
0001390478-16-000134.txt	Edgar Link	pending
0001390478-16-000134-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20160630.xml	Edgar Link	completed
gale-20160630.xsd	Edgar Link	pending
gale-20160630x10q.htm	Edgar Link	pending
gale-20160630_cal.xml	Edgar Link	unprocessable
gale-20160630_def.xml	Edgar Link	unprocessable
gale-20160630_lab.xml	Edgar Link	unprocessable
gale-20160630_pre.xml	Edgar Link	unprocessable
gale20160630ex311.htm	Edgar Link	pending
gale20160630ex312.htm	Edgar Link	pending
gale20160630ex321.htm	Edgar Link	pending
logo-verticala10.jpg	Edgar Link	pending
logo-verticala11.jpg	Edgar Link	pending
pipeline8092016.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2016 Q2 Form 10-Q Financial Statement

#000139047816000134 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2016 Q2 Form 10-Q Financial Statement

#000139047816000134 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls